Improvements in patient-reported outcomes: a prospective, non-interventional study with aclidinium bromide for treatment of COPD
The inhaled long-acting muscarinic antagonist aclidinium bromide has been shown to significantly improve lung function parameters and symptom severity in patients with COPD in randomised placebo- and active-controlled clinical studies. To obtain a comprehensive view of the treatment effects, patient-reported outcomes were investigated in a real-life COPD population in routine clinical practice in Austria. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - February 17, 2015 Category: Respiratory Medicine Authors: Katharina Marth, Elisabeth Schuller, Wolfgang Pohl, On behalf of the A NEED team Source Type: research
Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression
Conclusion:
All LAMAs were equally effective in preventing moderate-to-severe exacerbations. Aclidinium was associated with the lowest risk for severe exacerbations when treatment duration was 6 months or longer. The concomitant use of LABA may not enhance the efficacy of LAMAs in preventing COPD exacerbations. More studies are needed to further examine above findings. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - January 29, 2015 Category: Respiratory Medicine Authors: Oba, Y., Lone, N. A. Tags: Original Research Source Type: research
Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease
Expert Opinion on Pharmacotherapy, Volume 16, Issue 3, Page 427-434, February 2015. (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - January 19, 2015 Category: Drugs & Pharmacology Tags: article Source Type: research
Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression.
CONCLUSION: All LAMAs were equally effective in preventing moderate-to-severe exacerbations. Aclidinium was associated with the lowest risk for severe exacerbations when treatment duration was 6 months or longer. The concomitant use of LABA may not enhance the efficacy of LAMAs in preventing COPD exacerbations. More studies are needed to further examine above findings.
PMID: 25586493 [PubMed - as supplied by publisher] (Source: Respiratory Care)
Source: Respiratory Care - January 12, 2015 Category: Respiratory Medicine Authors: Oba Y, Lone NA Tags: Ther Adv Respir Dis Source Type: research
Overall and cardiovascular safety of aclidinium bromide in patients with COPD: Results of a pooled analysis
ConclusionsAclidinium has a good safety profile with no evidence of increased CV or cerebrovascular risk compared with placebo. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Chapman, K. R., Beck, E., Alcaide, D., Garcia Gil, E. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Analysis of comorbidities and treatment patterns by GOLD 2013 criteria: Pooled data from Phase III aclidinium bromide studies
ConclusionsPrescribing patterns for patients with COPD did not reflect guidelines, with frequent ICS use in Groups A and B. Patients in all groups had co-morbidities potentially affected by ICS use; these need to be considered before prescribing ICSs to patients with COPD. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Price, D., Thomas, M., Lamarca, R., Garcia Gil, E. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification
ConclusionsAclidinium improved dyspnoea and health status regardless of GOLD Group. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Mroz, R. M., Ausin, M. P., Lamarca, R., Garcia Gil, E. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies
ConclusionOverall, both doses of aclidinium/formoterol FDC BID had CV and CBV safety profiles similar to placebo and/or monotherapies. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Donohue, J. F., Bateman, E. D., D'Urzo, A., Shrestha, P., Leselbaum, A., Lei, A. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies
ConclusionIn a study population where prior exacerbation was not an inclusion criterion, aclidinium/formoterol 400/12 µg FDC reduced the rate of COPD exacerbations defined by HCRU or EXACT. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Bateman, E., Rennard, S., Jones, P., Molins, E., Jin, M., Leselbaum, A. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial
Conclusions:
These results suggest that aclidinium significantly improves exercise endurance, exertional dyspnea, hyperinflation, and physical activity in patients with COPD.Trial registration: ClinicalTrials.gov identifier: NCT01471171; URL: www.clinicaltrials.gov. (Source: BMC Pulmonary Medicine)
Source: BMC Pulmonary Medicine - December 23, 2014 Category: Respiratory Medicine Authors: Kai BeehHenrik WatzLuis Puente-MaestuLuis de TeresaDiana JarretaCynthia CaractaEsther GilHelgo Magnussen Source Type: research
Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients
CONCLUSIONS: In moderate to severe COPD patients, FDCs of aclidinium/formoterol improved respiratory symptoms compared with placebo and monotherapies over 6 months. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Jones, P., D'Urzo, A., Rennard, S., Molins, E., Mergel, V., Caracta, C., Leselbaum, A. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
CONCLUSIONS: Fixed-dose combination of aclidinium/formoterol showed rapid and sustained improvements in bronchodilation compared with each monotherapy and placebo, with numerically greater improvements observed with FDC 400/12 vs FDC 400/6. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Singh, D., D'Urzo, A., Jones, P., Serra, C., Mergel, V., Caracta, C., Leselbaum, A. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Interaction between aclidinium bromide and formoterol fumarate; effects on human bronchial smooth muscle
Conclusions: Aclidinium and formoterol at low concentrations synergistically inhibited smooth muscle tone. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Cazzola, M., Calzetta, L., Page, C. P., Facciolo, F., Gavalda, A., Matera, M. G. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies
ConclusionsOverall, the safety profile of FDC BID was comparable with placebo and with the individual monotherapies. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Korn, S., Kerwin, E., Donohue, J. F., Shrestha, P., Leselbaum, A., Lei, A. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies
ConclusionAclidinium significantly reduced the rate of moderate-to-severe and exacerbations of any severity vs placebo for all patients and particularly those in GOLD Group B+D. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 23, 2014 Category: Respiratory Medicine Authors: Wedzicha, J. A., Donaldson, G., Chuecos, F., Garcia Gil, E. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
